1[1]Gaytant MA, Steegers EA, Semmekrot BA, et al. Congenital cytomegalovirus infection: review of the epidemiology and outcome [ J ]. Obstet Gynecol Surv,2002,57(4) :245 - 256.
2[2]Bankier AT, Beck S, Bohni R, et al. The DNA sequence of the human cytomegalovirus genome [J].DNA Seq, 1991,2(1): 1 - 12.
3[3]Hensel G, Meyer H, Gartner S, et al. Nuclear location of human cytomegalovirus tegument protein pp150 (ppUL32) [J]. J Gen Virol, 1995,76:1591 - 1601.
4[4]Dal MP, Bessia C, Ripalti A, et al. Stabley expressed antisense RNA to cytomegalovirus UL 83 inhibits viral replication[J]. J Virol, 1996,70(4) :2086 - 2094.
5[5]Schmolke S, Kern H, Drescher P, et al. The dominant phosphoprotein pp65 (UL 83) of huamn cytomegalovirus is dispensable for growth in cell culture[J]. J Gen Virol, 1995,69 (10): 5959 - 5968.
6[6]Vaz SJ, Lule J, Rohrlich P, et al. Ex vivo stimulation and expansion of both CD4 ( + ) and CD8 ( + ) T cells from peripheral blood mononuclear cells of human cytomegalovirus-seropositive blood donors by using a soluble recombinant chimeric protein, IE1-pp65 [ J ]. J Virol, 2001,75 (17): 7840 - 7847.
7[7]Wills MR, Carmichael A, Mynard K, et al. The human cytotoxic T-lymphocyte (CTL) response to cytomegalovirus is dominated by structureal protein pp65:frequency, specificity, and T-cell receptor usage of pp65-specific CTL[J]. J Virol, 1996, 70 ( 11 ): 7569 -7579.
8[8]Gyulai Z, Endresz V, Burian K, et al. Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, ppl50, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs[J]. J Infect Dis,2000,181 (5): 1537 - 1546.
9[9]Diamond DJ, York J, Sun JY, et al. Development of a candidate HLA A 0201 restricted peptide-based vaccine against human cytomegalovirus infection [ J ]. Blood,1997,90:1751 - 1767.
10[10]Beninga J, Kropff B, Mach M, et al. Comparative analysis of fourteen individual HCMV proteins for helper T cell response[ J ]. J Gen Virol, 1995,76 (pt. 1 ):153 - 160.
